Gilead Sciences, Inc EV/EBITDA
Data as of August 04, 2026
EV/EBITDA
16.28
Enterprise Value
$176.21B
EBITDA (TTM)
$10.82B
Sector
Biotechnology
How It's Calculated
16.28 = $176.21B ÷ $10.82B
What This Means
Gilead Sciences, Inc's EV/EBITDA of 16.3 is in a moderate range for Biotechnology.
About Gilead Sciences, Inc
Gilead Sciences, Inc (GILD) operates in the Biotechnology sector, specifically in Biotechnology. With a market capitalization of about $161.66B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $131.15, within a 52-week range of $108.46 to $157.29 (-16.6% from the high, +20.9% from the low). Beta of 0.34 indicates relatively lower volatility versus the market.
Trailing profit margin is about 31.0%, signaling a strong profit margin relative to many peers.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Gilead Sciences, Inc, the ratio should be read with growth, capex needs, and cycle position in Biotechnology. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 16.28x EV/EBITDA, Gilead Sciences, Inc (GILD) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $176.21B and EBITDA near $10.82B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the GILD metrics hub for related valuation pages.
Sector Comparison
Among Biotechnology names on our S&P 100 coverage, Gilead Sciences, Inc's EV/EBITDA of 16.28 can be compared with peers such as AMGN (17.30), REGN (19.21). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Biotechnology stocks.
Key Takeaways
- GILD is grouped in the Biotechnology sector for peer comparisons.
- Recent beta of 0.34 suggests lower-than-market price sensitivity.
- Trailing profit margin of 31.0% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for GILD.
Learn the full workflow
Compare PE with PB, PEG, EV/EBITDA, and market cap in one structured path.
Open the Stock Valuation hub →Other GILD Metrics
Frequently Asked Questions
What is GILD's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Gilead Sciences, Inc's ratio is about 16.28 — common for comparing leveraged companies in Biotechnology.
Is 16.28 high or low vs peers?
Among Biotechnology peers (e.g. REGN (19.21), AMGN (17.30)), GILD's 16.28 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →